This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Phytiva Brand Gets Set To Release Cannabis Based Formulations Product Lines For The Multi-Billion Dollar Medical Cannabis Market, Newly Opened Social Use, And OTC Markets By Issuing A Stronger Outlook For 2013

DALLAS, Dec. 19, 2012 /PRNewswire/ -- X-Change Corp (NASDAQ OTC: XCHC), a U.S. boutique company whose niche is cannabis and hemp based extracts targeting Medical Cannabis, Cosmeceutical and Neutroceuticals and Social Usage solutions through multiple Phytiva Brand Product Lines. The Company issues a stronger outlook for 2013 based on new Phytiva Product Lines for the Medical Cannabis Industry as a whole. These new Phytiva Product Lines will be launched with Cannabis based formulations through Medical Cannabis dispensaries, Cannabis laboratories, and individual legal State grow operations on a State by State approved basis.   

The Company is working with approved partners operating in legal jurisdictions under State approved permits developing its newest Cannabis based Phytiva Product lines that have identified over a dozen ailments that we believe that our products will be the superior choice on the market.  These ailments include cancer, arthritis, influenza, HIV/ AIDS, PTSD and many more.

The global markets that the Phytiva product lines are targeting is enormous.  The Cancer industry is estimated at $300 billion globally by 2025, the HIV Therapeutics market is estimated to be $21.8 Billion by 2018.  This is in addition to the PTSD Therapeutics market which was worth $1.3 Billion in 2011.  Recently, a cure for Cancer, if realized, is estimated to be worth over $ 1 trillion. Social use has just become available in Washington State and Oregon, many numbers are reported very high, but the Company is awaiting official word.

X-Change Corporation through its Phytiva Brand Product line intends  to release product formulations that include high-level CBD's and variations of THC, CBD's, and other cannabinoid elements. These formulations will be in addition to the existing development of the hemp extract based products forthcoming in 2013.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs